Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
2.070
+0.050 (2.48%)
Dec 5, 2025, 4:00 PM EST - Market closed
Inovio Pharmaceuticals Revenue
Inovio Pharmaceuticals had revenue of $182.34K in the twelve months ending September 30, 2025, down -10.36% year-over-year. In the year 2024, Inovio Pharmaceuticals had annual revenue of $217.76K, down -73.83%.
Revenue (ttm)
$182.34K
Revenue Growth
-10.36%
P/S Ratio
779.96
Revenue / Employee
$1,361
Employees
134
Market Cap
142.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.76K | -614.25K | -73.83% |
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.06M | 70.32% |
| Dec 31, 2019 | 4.35M | -26.30M | -85.80% |
| Dec 31, 2018 | 30.65M | -25.38M | -45.29% |
| Dec 31, 2017 | 56.03M | -8.21M | -12.78% |
| Dec 31, 2016 | 64.25M | 9.98M | 18.39% |
| Dec 31, 2015 | 54.27M | 41.25M | 316.88% |
| Dec 31, 2014 | 13.02M | -4.25M | -24.62% |
| Dec 31, 2013 | 17.27M | 9.69M | 127.92% |
| Dec 31, 2012 | 7.58M | -11.45M | -60.17% |
| Dec 31, 2011 | 19.02M | 6.73M | 54.79% |
| Dec 31, 2010 | 12.29M | -5.82M | -32.16% |
| Dec 31, 2009 | 18.11M | 15.00M | 481.09% |
| Dec 31, 2008 | 3.12M | -4.64M | -59.83% |
| Dec 31, 2007 | 7.76M | 1.79M | 29.91% |
| Dec 31, 2006 | 5.97M | -3.47M | -36.73% |
| Dec 31, 2005 | 9.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INO News
- 4 days ago - Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 18 days ago - INOVIO to Participate in December Investor Conferences - PRNewsWire
- 24 days ago - Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress - Seeking Alpha
- 25 days ago - INOVIO Announces Pricing of $25 Million Public Offering - PRNewsWire
- 26 days ago - Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - INOVIO Announces Proposed Public Offering - PRNewsWire
- 26 days ago - INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 4 weeks ago - INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults - PRNewsWire